Skip to content

A Clinical Evaluation of a Unani Drug on Uterine Fibroid

A Clinical Evaluation of a Unani Polyherbal Formulation in Management of Sala-e-Reham ( Uterine Fibroid) - An Open Label Single Arm Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044543
Enrollment
40
Registered
2022-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N80-N98- Noninflammatory disorders of female genital tract

Interventions

Intervention1: Extract of Unani Polyherbal Formulation- Kachnar (Bauhinia purpurea Linn), Muqil (Commiphora mukul), Rasaut (Berberis aristata), Sambhalu (Vitex negundo), Kasni ( Cichorium intybus), Tu

Sponsors

Ayurvedic and Unani Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women in reproductive age group(20-45years) diagnosed with uterine fibroid upto 2-3cm. Patient coming with pelvic pain, pelvic lump, menorrhagia with regular cycles. Patient willing to sign the informed consent follow the protocol and participate in clinical trial voluntarily.

Exclusion criteria

Exclusion criteria: Patient unwilling to sign the consent form. Patients who have abnormal finding such as hemorrhagic cyst, tubo-ovarian mass, suspected pregnancy, bicornuate uterus and septate uterus in ultrasonography will be excluded from the study. Patient taking Hormonal therapy. Patient having history of AIDS, Syphilis, and Gonorrhea. History of Cardiovascular, Renal and Liver Disease. History of Diabetes (Type 1 or Type 2) History of Thyroid disease. History of Bleeding disorder. Patient having IUCD. Patients with systemic disease and malignancy.

Design outcomes

Primary

MeasureTime frame
To reduce the size of fibroid To assess the safety of the proposed Unani polyherbal formulations in the management of Sala-e-reham (Fibroadenoma of Uterus) To assess the efficacy of the proposed Unani polyherbal formulations in the management of Sala-e-reham (Fibroadenoma of Uterus) Timepoint: 3 months

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Anam Habib

Ayurvedic and Unani Tibbia College and Hospital

draysharaza11@gmail.com9354925031

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026